VivoSeq
Other

Testosterone Replacement Therapy

0

Pipeline Programs↗

1

Active Trials↗

1

Companies Involved↗

Testosterone Replacement Therapy is an early-stage landscape with 0 programs across 1 company. The most active players are AbbVie.

Intelligence

Pipeline Metrics

Competitive Density

6/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

AbbVie logo

AbbVie

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

4

clinical trials

Completed3 · 75%
Active, not recruiting1 · 25%

Clinical Trials

Trial Activity

A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascular Events (MACE) and Efficacy Measures in Hypogonadal Men
Completed·AbbVie logoAbbVie·Phase 4·NCT03518034·5,246 enrolled
Study on Effects of Testosterone Replacement Therapy in Hypogonadal Type 2 Diabetic Patients" (SETH2)
Completed·UUniversity Medical Centre Ljubljana·Phase 4·NCT03792321·55 enrolled
Perioperative Testosterone Replacement Therapy for the Improvement of Post-Operative Outcomes in Patients With Low Testosterone
Active, not recruiting·EEmory University·Phase 1·NCT04731376·56 enrolled
Study to Determine the Effects of Testosterone Replacement Therapy in Aging Men With Androgen Deficiency
Completed·—·Phase 2/3·NCT00161304·44 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)